Welcome to our dedicated page for Exicure SEC filings (Ticker: XCUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to untangle the science, risks, and insider moves buried in Exicure’s SEC paperwork? Biotech filings often exceed 200 pages, packed with complex trial data and SNA-technology jargon. If you need Exicure SEC filings explained simply, start here.
Stock Titan’s platform delivers real-time access to every document the company submits to EDGAR—from an Exicure quarterly earnings report 10-Q filing that details cash burn and collaboration revenue, to an Exicure 8-K material events explained alert when pipeline setbacks or licensing deals hit the wire. Our AI reads each section, summarizes R&D milestones, and flags red-flag language so you can focus on decisions, not decoding. You’ll also find Exicure Form 4 insider transactions real-time alongside a historical log of Exicure insider trading Form 4 transactions, making it easy to monitor executive sentiment.
Looking for deeper context? Use our side-by-side views for an Exicure earnings report filing analysis, or jump straight to risk-factor comparisons inside the Exicure annual report 10-K simplified. Need governance details before proxy season? The Exicure proxy statement executive compensation section breaks out pay packages, option grants, and board independence. And when timing matters, instant alerts spotlight every Exicure executive stock transactions Form 4 so you never miss a market-moving trade. Whether you’re a portfolio manager, sell-side analyst, or simply understanding Exicure SEC documents with AI, our comprehensive, AI-powered tools turn dense biotech disclosures into actionable insight.
Exicure, Inc. (Nasdaq: XCUR) filed its Form 10-Q for the quarter ended March 31, 2025. The filing confirms that the company remains a non-accelerated filer and smaller reporting company and is not a shell company. All required SEC reports and interactive data files have been submitted on time over the past 12 months. As of June 23 2025, the company had 6,317,793 common shares outstanding.
The document contains the standard sections—unaudited balance sheet, income statement, cash-flow statement, changes in stockholders’ equity, MD&A, risk factors and legal proceedings—yet the excerpt provided does not include actual financial figures or narrative discussion. Therefore, no assessment can be made regarding revenue, expenses, cash position, or profitability for the period.
Key structural disclosures gleaned from the excerpt:
- Headquarters: 400 Seaport Court, Suite 102, Redwood City, CA 94063; phone (847) 673-1700.
- Securities registered: Common Stock, $0.0001 par, trading symbol XCUR on Nasdaq.
- Table of contents shows Management’s Discussion begins on page 27 and Risk Factors on page 38, indicating extensive narrative sections.
- The cautionary note reiterates that forward-looking statements are subject to material risks, with reference to the detailed risk factors section.
Material information such as cash burn, R&D spend, and operating loss is not present in the excerpt. Investors will need to consult the full filing to evaluate liquidity runway, milestone obligations, and any updates on ongoing collaborations or litigation.
Exicure, Inc. (Nasdaq: XCUR) filed a Form 8-K dated June 27, 2025 to furnish its financial and operational results for the quarter ended March 31, 2025. The disclosure falls under Item 2.02 – Results of Operations and Financial Condition and simply states that a detailed press release is attached as Exhibit 99.1. Because the information is "furnished" rather than "filed," it is not subject to Section 18 liability and will not be incorporated by reference unless explicitly cited in a future registration statement.
No revenue, earnings, cash-flow figures or guidance appear in the 8-K text provided, and no additional items such as material transactions or strategic updates are included. The only other exhibit is Exhibit 104, the standard Inline XBRL cover-page data file. All remaining content—registration details, securities listing, emerging-growth-company status, and officer signature—matches routine SEC formatting.
Key takeaway for investors: today’s 8-K serves as a procedural notice that the Q1 2025 results press release is now available. Investors must review Exhibit 99.1 to assess the actual performance metrics and forward-looking commentary.
FAQ
What is the current stock price of Exicure (XCUR)?
What is the market cap of Exicure (XCUR)?
What is the core technology behind Exicure Inc?
Which therapeutic areas does Exicure focus on?
How does SNA technology differentiate Exicure from other biotech companies?
What is the business model of Exicure Inc?
How does Exicure Inc enhance the efficacy of its treatments?
Does Exicure Inc target only a single disease area?
What are the advantages of Exicure's approach in nucleic acid delivery?
How does Exicure Inc position itself within the biotech industry?
